Adherence trends for 3 chronic disease medication classes among differently insured populations

American Journal of Pharmacy Benefits

Volumn 6, Issue 1, 2014, Pages

  Erickson, Sara C ^a   Leslie, R Scott ^a   Qiu, Wenyi ^a   Patel, Bimal V ^a  

^a MedImpact Healthcare Systems Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL ANTIDIABETIC AGENT; RENIN INHIBITOR; STATIN (PROTEIN);

ARTICLE; CHRONIC DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; GOVERNMENT; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; HYPERTENSION; MEDICAID; MEDICARE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SAFETY; PHARMACY BENEFIT MANAGER; PHARMACY QUALITY ALLIANCE; PROPORTION DAYS COVERED; RETROSPECTIVE STUDY;

EID: 84896349361     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Kochanek KD, Xu JQ, Murphy SL, Miniño AM, Kung HC. US Department of Health and Human Services. National Vital Statistics Reports. Deaths: final data for 2009. http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_03.pdf. Published December 29, 2011. Accessed January 15, 2014.
2. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933-944.
3. Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther. 2003;25(11):2958-2971.
4. Dragomir A., Côté R, Roy L, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48(5): 418-425.
5. Khanna R, Pace PF, Mahabaleshwarkar R, et al. Medication adherence among recipients with chronic disease enrolled in a state Medicaid program. Popul Health Manag. 2012;15(5):253-260.
6. Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care. 2010;16(8):568-576.
7. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011;30(1):91-99.
8. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6): 521-530.
9. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol. 2007;166(3)348-354.
10. LaFleur J, Nelson RE, Sauer BC, Nebeker JR. Overestimation of the effects of adherence on outcomes: a case study in healthy user bias and hypertension. Heart. 2011;97(22):1862-1869.
11. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836-1841.
12. Schultz JS, O'Donnell JC, McDonough KL, Sasane R, Meyer J. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care. 2005;11(5):306-312.
13. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-47.
14. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565-574.
15. Sattler ELP, Lee JS, Perri M 3rd. Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature. Drugs Aging. 2013;30(6):383-399.
16. Vink NM, Klungel OH, Stolk RP, Denig P. Comparison of various measures for assessing medication refi ll adherence using prescription data. Pharmacoepidemiol Drug Saf. 2009;18(2):159-165.
17. Nau DP. Proportion of Days Covered (PDC) as a preferred method of measuring medication adherence. Pharmacy Quality Alliance website. http://www.pqaalliance.org/images/uploads/files/PQA%20PDC%20vs%20%20MPR.pdf. Accessed January 15, 2014.
18. Martin BC, Wiley-Exley EK, Richards S, et al. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009;43(1):36-44.
19. Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15(7):457-464.
20. Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cut-point for adherent measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303-2310.
21. Choudhry NK, Glynn RJ, Avorn J, et al. Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes. Am Heart J. 2014;167(1):51-58.
22. National Quality Forum. National Quality Forum endorses measures to improve medication safety and quality. http://www.qualityforum.org/News_And_Resources/Press_Releases/2009/National_Quality_Forum_Endorses_Measures_to_Improve_Medication_Safety_and_Quality.aspx. Accessed January 13, 2014.
23. Centers for Medicare & Medicaid Services. Enhancements to Medicare Part D Patient Safety Reports and website. http://www.cms.gov/Medicare/Prescription_Drug_Coverage/PrescriptionDrugCovContra/downloads/2010PtSafetyReportEnh an_memo_093010.pdf. Published September 30, 2010. Accessed January 13, 2014.
24. National Committee for Quality Assurance (NCQA). HEDIS 2014 Technical Specifi cations. Washington, DC: NCQA; 2013.
25. Utilization Review Accreditation Commission (URAC). Pharmacy Benefit Management Version 2.0 and Version 2.1, Measures Version 1.1. https://www.urac.org/wp-content/uploads/PBM_Measures_AtAGlance.pdf. Accessed January 16, 2014.
26. Academy of Managed Care Pharmacy (AMCP). The Academy of Managed Care Pharmacy responded to a URAC call for public comment on performance measures for health plan accreditation. http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=10681. Published May 18, 2011. Accessed January 16, 2014.
27. Department of Health and Human Services. Part 156-Health insurance issuer standards under the Affordable Care Act, including standards related to exchanges. Federal Register 2012;77(108):33133-33142. http://www.gpo.gov/fdsys/pkg/FR_2012-06-05/pdf/2012-13489.pdf. Accessed January 16, 2014.
28. Centers for Medicaid & Medicare Services. Health insurance exchanges; application by the Accreditation Association for Ambulatory Health Care to be a recognized accrediting entity for the accreditation of qualified health plans. https://www.federalregister.gov/articles/2013/09/13/2013_22369/health_insurance-exchanges- application-by-the-accreditation-association-for-ambulatory-health-care Published September 13, 2013. Accessed January 16, 2014.
29. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9): 728-740.
30. Centers for Medicare & Medicaid Services. Medicare 2014 Part C & D Star Rating technical notes. http://www.cms.gov/Medicare/Prescription_Drug_Coverage/PrescriptionDrugCovGenIn/PerformanceData.html. Accessed January 31, 2013.
31. Pharmacy Quality Alliance. PQA measures used by CMS in the Star Ratings. http://pqaalliance.org/measures/cms.asp. Accessed January 31, 2013.
32. Leslie RS, Gwadry-Sridhar F, Thiebaud P, et al. Calculating medication compliance adherence and persistence in administrative pharmacy claims databases. Pharmaceut Program. 2008;1(1):13-19.
33. Gibson TB, Lee TA, Vogeli CS, et al. A four-system comparison of patients with chronic illness: the military health system, veterans health administration, Medicaid, and commercial plans. Mil Med. 2009;174(9):936-943.
34. Landon BE, Schneider EC, Normand SL, Scholle SH, Pawlson LG, Epstein AM. Quality of care in Medicaid managed care and commercial health plans. JAMA. 2007;298(14):16-81.
35. Zhang JX, Huang ES, Drum ML, et al. Insurance status and quality of diabetes care in community health centers. Am J Public Health. 2008;99(4):742-747.
36. Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment predictors of statin adherence. Med Care. 2010;48(3):196-202.
37. Ishisaka DY, Jukes T, Romanelli RJ, Wong KS, Schiro TA. Disparities in adherence to and persistence with antihypertensive regimens: an exploratory analysis from a community-based provider network. J Am Soc Hypertens. 2012;6(3): 201-209.
38. Mann DM, Allegrante JP, Natarajan S, Halm EA, Charlson M. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther. 2007;21(4): 311-316.
39. Schneewiess S, Patrick AR, Maclure M, Dormuth CR, Glynn RJ. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation. 2007;115(16): 2128-2135.
40. Sharma KP, Taylor TN. Pharmacy effect on adherence to antidiabetic medications. Med Care. 2012;50(8):685-691.
41. Shaya FT, Du D, Gbrarayor CM, et al. Predictors of compliance with antihypertensive therapy in a high-risk Medicaid population. J Natl Med Assoc. 2009; 101(1):34-39.
42. Gibson TB, Mark TL, McGuigan KA, Axelsen K, Wang S. The effects of prescription drug copayments on statin adherence. Am J Manag Care. 2006;12(9): 509-517.
43. Gu Q, Zeng F, Patel BV, Tripoli LC. Part D coverage gap and adherence to diabetes medications. Am J Manag Care. 2010;16(12):911-918.
44. Kuo YF, Rajii MA, Markides KS, et al. Inconsistent use of diabetes medications, diabetes complications and mortality in older Mexican Americans over a 7-year period: data from the Hispanic established population for the epidemiologic study of the elderly. Diabetes Care. 2003;26(11):3054-3060.
45. Morrell RW, Park DC, Kidder DP, Martin M. Adherence to antihypertensive medications across the life span. Gerontologist. 1997;37(5):609-619.
46. Weingarten MA, Cannon BS. Age as a major factor affecting adherence to medication for hypertension in a general practice population. Fam Pract. 1988; 5(4):294-296.
47. Insel K, Morrow D, Brewer B, Figueredo A. Executive function, working memory, and medication adherence among older adults. J Gerontol B Psychol Sci Soc Sci. 2006;61(2):P102-P107.
48. Finucane ML, Slovic P, Hibbard JH, et al. Aging and decision-making competence: an analysis of comprehension and consistency skills in older versus younger adults considering health plan options. J Behav Decis Mak. 2002;15(2): 141-164.
49. Medicare Payment Advisory Commission. Report to the Congress: Medicare payment policy. http://www.medpac.gov/documents/Mar13_entirereport.pdf. Published March 2013. Accessed January 14, 2014.
50. Priest JL, Cantrell R, Fincham J, et al. Quality of care associated with common chronic diseases in a 9-state Medicaid population utilizing claims data: an evaluation of medication and health care use and costs. Popul Health Manag. 2011;14:43-54.
51. Zhang Q, Zhao C, Davies MJ, Radican L, Seck T. Compliance and persistence with concomitant statin and oral antihyperglycemic therapy. Am J Manag Care. 2011;17(11):746-752.
52. Gerber BS, Cho YI, Arozullah AM, Lee SY. Racial differences in medication adherence: a cross-sectional study of Medicare enrollees. Am J Geriatr Pharmacother. 2010;8(2):136-145.
53. Maciejewski ML, Bryson CL, Perkins M, et al. Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications. Am J Manag Care. 2010;16(1):e20-e34.
54. Pesa JA, Van Den Bos J, Gray T, et al. An evaluation of the impact of patient cost sharing for antihypertensive medications on adherence, medication and health care utilization, and expenditures. Patient Prefer Adherence. 2012;6: 63-71.
55. Piette JD, Wagner TH, Potter MB, Schillinger D. Health insurance status, costrelated medication underuse, and outcomes among diabetes patients in three systems of care. Med Care. 2004;42(2):102-109.
56. Soumerai SB, Pierre-Jacquest M, Zhang F, et al. Cost-related medication nonadherence among elderly and disabled medicare benefi ciaries: a national survey 1 year before medicare drug benefi t. Arch Intern Med. 2006;166(17): 1829-1835